Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL96600 | 0.83 | PPARG (0.48) | PPARGMAPTALDH1A1NPSR1IL4I1 | |
| SCHEMBL13846781 | 0.73 | KDM4E (0.52) | MAPTALDH1A1NPSR1CA2MAOB | |
| SCHEMBL166570 | 0.72 | PPARG (0.74) | PPARGFFAR1MAPTALDH1A1NPSR1 | |
| SCHEMBL290413 | 0.72 | MAPT (0.75) | PPARGFFAR1MAPTALDH1A1NPSR1 | |
| SCHEMBL13846771 | 0.70 | CA2 (0.63) | PPARGMAPTALDH1A1CA2 | |
| SCHEMBL13846702 | 0.70 | PPARG (0.59) | PPARGFFAR1MAPTALDH1A1NPSR1 | |
| SCHEMBL13846766 | 0.70 | KDM4E (0.53) | ALDH1A1NPSR1MAOBMAOACISD1 | |
| SCHEMBL6866703 | 0.70 | PPARG (0.71) | PPARGFFAR1MAPTALDH1A1NPSR1 | |
| SCHEMBL8932685 | 0.68 | HDAC8 (0.53) | PPARGFFAR1MAPTALDH1A1NPSR1 | |
| SCHEMBL9372697 | 0.68 | PPARG (0.68) | PPARGFFAR1MAPTALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167045-A1 | Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin II type I receptor antagonist | MERCK & CO., INC. | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167045-A1 | Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin II type I receptor antagonist | AGTR2, AGTR1, PPARA | PPARG 4/4885FFAR1 15/4885MAPT 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.